The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Experts are sounding the alarm on a 'worrying' surge in dangerous weight-loss 'jab hacks' like microdosing Wegovy or sourcing from beauty therapists. A survey shows 32% of UK users microdose and 28% buy unlicensed drugs amid rising costs. Discover the real risks and expert advice for safe use.
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
Weight-loss drugs like Wegovy's new pill are making a splash with multimillion-dollar Super Bowl ads featuring Kenan Thompson, DJ Khaled, and Serena Williams. As Novo Nordisk and Eli Lilly battle for market share, affordable oral GLP-1 options starting at $49 signal a new era in obesity care. See how these celebrity spots aim to reach 130 million viewers.
A senior South African Police Service official admitted under oath to asking her boyfriend's company for Ozempic amid pharmacy shortages. Brigadier Rachel Matjeng's testimony at the Madlanga Commission highlights the drug's high demand for type 2 diabetes and off-label weight loss use. The case raises questions about procurement ethics in a corruption inquiry.
Tennis icon Serena Williams has shared her inspiring weight loss story, dropping 34 pounds with GLP-1 drugs after struggling post-retirement and motherhood. Facing unknown heart disease risks, she credits the medication with transforming her health. Inside her journey and how GLP-1 works for real results.
A 30-year-old woman from East Anglia discovered her rare gigantomastia condition—causing her breasts to weigh 39 lbs.—while losing weight on Mounjaro. Despite rapid breast growth amid overall weight loss, she faces numb arms, scarring, and breathing issues. Her story highlights the unexpected challenges of GLP-1 medications like tirzepatide.
When Terra Field switched from Wegovy to Zepbound, her weight loss resumed after a plateau, silencing the 'food noise' she'd battled since childhood. Now, next-generation GLP-1 drugs like CagriSema and retatrutide promise even greater results by targeting multiple gut hormones. But as these stronger treatments advance, experts caution about the risks of losing too much weight too fast.
A Liverpool mum shed 7st on Mounjaro in under a year, transforming her life—but a freezing side effect dubbed 'MJ Freeze' has spiked her energy bills by £70 a month. Emilly Murray now layers up at home with heated blankets and gloves just to stay warm. Despite the chill, she says it's worth every penny for silencing food noise and boosting her health.
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
